Back
Publications about genetic testing for neurological disorders
  1. Utility of a CENTOGENE-developed biomarker

Utility of a CENTOGENE-developed biomarker

June 21, 2019

Gluosylsphingosine (lyso-Gb1) as a biomarker for monitoring treated and untreated children with Gaucher disease

Metabolic biomarkers are well-accepted diagnostic tools, and may also qualify for monitoring purposes. The longitudinal dynamics of Lyso-Gb1, an established diagnostic biomarker for Gaucher disease (GD), was recently determined using CENTOGENE’s corresponding mass-spectrometry assay. Based on excellent prognostic performance of Lyso-Gb1, an inclusion in routine follow up of GD patients was recommended. The study was published in the June issue of International Journal of Molecular Sciences.